Dementia with Lewy bodies care formalises around alpha-synuclein-aware management
Cholinesterase inhibitor optimisation, antipsychotic-avoidance protocols, RBD recognition pathways, and emerging alpha-synuclein-targeted programs are reshaping DLB care.
Dementia with Lewy bodies (DLB) has been an underrecognised category often misdiagnosed as Alzheimer's or Parkinson's dementia. Structured diagnostic criteria and biomarker-based approaches (DAT-SPECT imaging, cardiac MIBG) are formalising, cholinesterase inhibitor use is established as first-line in DLB, antipsychotic-avoidance protocols are formalising given severe sensitivity in DLB, and emerging alpha-synuclein-targeted programs (covered in earlier neurology rounds for Parkinson's) are reading out in DLB. The diagnostic-recognition gap is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Key sources
Related
- ExplainedWhat is spasticity?
- SnapshotAcute ischemic stroke therapy reference (2026)
- ExplainedAcute ischemic stroke explained